Sources and significance of plasma levels of catechols and their metabolites in humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 3, 2003, Pages 800-811

  Goldstein, David S ^a   Eisenhofer, Graeme ^a   Kopin, Irwin J ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ADRENALIN; CATECHOL DERIVATIVE; CATECHOLAMINE DERIVATIVE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE DERIVATIVE; HOMOVANILLIC ACID; LEVODOPA; NORADRENALIN; NORMETADRENALIN; VANILMANDELIC ACID;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; CATECHOLAMINE BLOOD LEVEL; DOPAMINE BLOOD LEVEL; METABOLITE; NORADRENALIN BLOOD LEVEL; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; REVIEW;

ANIMALS; CATECHOLAMINES; CATECHOLS; DIHYDROXYPHENYLALANINE; HUMANS; METHOXYHYDROXYPHENYLGLYCOL; NOREPINEPHRINE; NORMETANEPHRINE; VANILMANDELIC ACID;

EID: 0038526391     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.049270     Document Type: Review

References (46)

1. Axelrod FB, Goldstein DS, Holmes C, and Kopin IJ (1998) Genotype and phenotype in familial dysautonomia. Adv Pharmacol 42:925-928.
2. Biaggioni I, Goldstein DS, Atkinson T, and Robertson D (1990) Dopamine-βhydroxylase deficiency in humans. Neurology 40:370-373.
3. Bornstein S, Breidert M, Ehrhart-Bornstein M, Kloos B, and Scherbaum W (1995) Plasma catecholamines in patients with Addison's disease. Clin Endocrinol 42: 215-218.
4. Buu NT and Lussier C (1990) Origin of dopamine in the rat adrenal cortex. Am J Physiol 258:F287-F291.
5. Charney DS, Heninger GR, and Breier A (1984) Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psych 41:751-763.
6. +-homoeostasis. Acta Med Scand Suppl 672:111-115.
7. Eisenhofer G, Aneman A, Friberg P, Hooper D, Fandriks L, Lonroth H, Hunyady B, and Mezey E (1998a) Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 42:374-377.
8. Eisenhofer G, Aneman A, Hooper D, Holmes C, Goldstein DS, and Friberg P (1995) Production and metabolism of dopamine and norepinephrine in mesenteric organs and liver of swine. Am J Physiol 268:G641-G649.
9. Eisenhofer G, Aneman A, Hooper D, Rundqvist B, and Friberg P (1996) Mesenteric organ production, hepatic metabolism and renal elimination of norepinephrine and its metabolites in humans. J Neurochem 66:1565-1573.
10. Eisenhofer G, Coughtrie MWH, and Goldstein DS (1999) Dopamine sulfate: an enigma resolved. Clin Exp Pharmacol Physiol 26:S41-S53.
11. Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO 3rd, Quyyumi AA, Lambert G, Chin J, Jennings GL, and Goldstein DS (1992) Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 85:1775-1785.
12. Eisenhofer G, Goldstein DS, Ropchak TG, and Kopin IJ (1988) Source and physiological significance of plasma 3,4-dihydroxyphenylalanine in the rat. J Neurochem 51:1204-1213.
13. Eisenhofer G, Goldstein DS, Stull RW, Gold PW, Keiser HR, and Kopin IJ (1987) Dissociation between corticotrophin and catecholamine responses to isoprenaline in humans. Clin Exp Pharmacol Physiol 14:337-341.
14. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh T-T, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A, and Lenders J (1998b) Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 83:2175-2185.
15. Eisenhofer G, Pecorella W, Pacak K, Hooper D, Kopin IJ, and Goldstein DS (1994) The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. J Auton Nerv Syst 50:93-107.
16. Eisenhofer G, Walther M, Huynh T-T and al. e (2001) Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86:1999-2008.
17. Eldrup E, Clausen N, Scherling B, and Schmiegelow K (2001) Evaluation of plasma 3,4-dihydroxyphenylacetic acid (DOPAC) and plasma 3,4-dihydroxyphenylalanine (DOPA) as tumor markers in children with neuroblastoma. Scand J Clin Lab Invest 61:479-490.
18. Esler M (2000) The sympathetic system and hypertension. Am J Hypertens 13:99S-105S.
19. Esler MD, Turner AG, Kaye DM, Thompson JM, Kingwell BA, Morris M, Lambert GW, Jennings GL, Cox HS, and Seals DR (1995) Aging effects on human sympathetic neuronal function. Am J Physiol 268:R278-R285.
20. Goldstein DS, Cannon RO, Quyyumi A, Chang P, Duncan M, Brush JE Jr, and Eisenhofer G (1991) Regional extraction of circulating norepinephrine, DOPA and dihydroxyphenylglycol in humans. J Auton Nerv Sys 34:17-35.
21. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, and Kopin IJ (1988) Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Investig 81:213-220.
22. Goldstein DS, Hahn S-H, Holmes C, Tifft C, Harvey-White J, Milstien S, and Kaufman S (1995) Monoaminergic effects of folinic acid, L-DOPA and 5-hydroxytryptophan in dihydropteridine reductase deficiency. J Neurochem 64:2810-2813.
23. 18F]fluorodopamine in humans. Clin Exper Hypertens 19:155-161.
24. Goldstein DS, Holmes C, Cannon RO III, Eisenhofer G, and Kopin IJ (1997) Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 336:696-702.
25. Goldstein DS, Levinson PD, Zimlichman R, Pitterman A, Stull R, and Keiser HR (1985) Clonidine suppression testing in essential hypertension. Ann Intern Med 102:42-49.
26. Goldstein DS, Polinsky RJ, Garty M, Robertson D, Brown RT, Biaggioni I, Stull R, and Kopin IJ (1989) Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol 26:558-563.
27. Goldstein DS, Spanarkel M, Pitterman A, Toltzis R, Gratz E, Epstein S, and Keiser HR (1982) Circulatory control mechanisms in vasodepressor syncope. Am Heart J 104:1071-1075.
28. Goldstein DS, Stull R, Eisenhofer G, Sisson JC, Weder A, Averbuch SD, and Keiser HR (1986) Plasma 3,4-dihydroxyphenylalanine (DOPA) and catecholamines in neuroblastoma or pheochromocytoma. Ann Int Med 105:887-888.
29. Goldstein DS, Swoboda KJ, Miles JM, Coppack SW, Aneman A, Holmes C, Eisenhofer G, and Lenders J (1999) Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab 84:2523-2531.
30. Goldstein DS, Udelsman R, Eisenhofer G, Stull R, Keiser HR, and Kopin IJ (1987) Neuronal source of plasma dihydroxyphenylalanine. J Clin Endocrinol Metab 64:856-861.
31. Grossman E, Goldstein DS, Hoffman A, and Keiser HR (1991) Glucagon and clonidine testing in the diagnosis of pheochromocytoma. Hypertension 17:733-741.
32. Kaler SG, Goldstein DS, Holmes C, Salerno JA, and Gahl WA (1993) Plasma and cerebrospinal fluid neurochemical pattern in Menkes' disease. Ann Neurol 33:171-175.
33. Kopin IJ, Rundqvist B, Friberg P, Lenders J, Goldstein DS, and Eisenhofer G (1998) Different relationships of spillover to release of norepinephrine in human heart, kidneys and forearm. Am J Physiol 275:R165-R173.
34. Kvetnansky R, Armando I, Weise VK, Holmes C, Fukuhara K, Deka-Starosta A, Kopin IJ, and Goldstein DS (1992) Plasma dopa responses during stress: dependence on sympathoneural activity and tyrosine hydroxylation. J Pharmacol Exp Ther 261:899-909.
35. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, and Eisenhofer G (1995) Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 123:101-109.
36. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, and Eisenhofer G (2002) Biochemical diagnosis of pheochromocytoma: which test is best? J Am Med Assoc 287:1427-1434.
37. Lenders JWM, Eisenhofer G, Abeling NGGM, Berger W, Murphy DL, Konings CH, Wagemakers LMB, Kopin IJ, Karoum F, van Gennip AH, and Brunner HG (1996) Specific genetic deficiencies of the A and B isozymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Investig 97:1010-1019.
38. Letellier S, Garnier JP, Spy J, and Bousquet B (1997) Determination of the L-DOPA/ L-tyrosine ratio in human plasma by high-performance liquid chromatography. Usefulness as a marker in metastatic malignant melanoma. J Chromatog B Biomed Applic 696:9-17.
39. Mathe A and Knapp P (1969) Decreased plasma free fatty acids and urinary epinephrine in bronchial asthma. N Engl J Med 281:234-238.
40. Merke D, Chrousos G, Eisenhofer G, Weise M, Keil M, Rogol A, Van Wyk J, and Bornstein S (2001) Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343:1362-1368.
41. Pacak K, Baffi JS, Kvetnansky R, Goldstein DS, and Palkovits M (1998) Stressorspecific activation of catecholaminergic systems: implications for stress-related hypothalamic-pituitary-adrenocortical responses. Adv Pharmacol 42:561-564.
42. Robertson D, Goldberg MR, Tung CS, Hollister AS, and Robertson RM (1986) Use of α2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system. J Clin Investig 78:576-581.
43. Swoboda KJ, Hyland K, Goldstein DS, Kuban KC, Arnold LA, Holmes CS, and Levy HL (1999) Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology 53:1205-1211.
44. Thompson JM, Wallin BG, Lambert GW, Jennings GL, and Esler MD (1998) Human muscle sympathetic activity and cardiac catecholamine spillover: no support for augmented sympathetic noradrenaline release by adrenaline co-transmission. Clinical Science (Wash DC) 94:383-393.
45. Wolfovitz E, Grossman E, Folio CJ, Keiser HR, Kopin IJ, and Goldstein DS (1993) Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans. Clin Sci (Colch) 84:549-557.
46. Yoshimatsu H, Oomura Y, Katafuchi T, and Niijima A (1987) Effects of hypothalamic stimulation and lesion on adrenal nerve activity. Am J Physiol 253: R418-R424.